文献速递脑血管病外科神经重症

颅内动静脉畸形的低分次放射外科治疗:系统综述与荟萃分析

Hypofractionated radiosurgery for intracranial arteriovenous malformations: a systematic review and meta-analysis.
PubMed 文献 · J Neurosurg · 2025-05-30

该系统综述与荟萃分析纳入29项研究共995例患者,评估低分次立体定向放射外科(HF-SRS)治疗颅内动静脉畸形的效果。HF-SRS的DSA确认闭塞率为50.1%(95%CI 35.2%-64.9%,I²=85.3%),随访41.2个月(95%CI 35.3-48.1个月,I²=95%),破裂率11.1%,新发癫痫5.5%,放射性坏死10.4%,AVM相关死亡率6%。光子与质子HF-SRS的闭塞率、破裂率和死亡率无显著差异。

要点

  • HF-SRS的DSA确认闭塞率为50.1%,放射性坏死10.4%,AVM相关死亡率6%。
  • 总剂量≥35 Gy较<35 Gy的闭塞率趋势更高(60.9% vs 47.8%,p=0.57),放射性坏死更高(19.9% vs 8.2%,p=0.02)。
  • 分次剂量≥7 Gy较<7 Gy的闭塞率趋势更高(53.5% vs 44.5%,p=0.64),放射性坏死更高(18% vs 6.2%,p=0.01)。

核心结论

  • HF-SRS是治疗AVM有前景的放射外科策略,光子与质子疗法的有效性和不良反应无统计学显著差异。
  • HF-SRS在AVM中的应用存在显著异质性,需要进一步研究并统一报告及纳入既往、辅助和挽救治疗。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和Embase中关于低分次、放射外科和动静脉畸形的文献,纳入29项研究共995例患者。
  • 对≥3项研究报告的变量进行荟萃分析,并针对光子和质子HF-SRS进行亚组分析。

主要发现

  • HF-SRS的DSA确认闭塞率为50.1%(95%CI 35.2%-64.9%,I²=85.3%),随访41.2个月(95%CI 35.3-48.1个月,I²=95%)。
  • HF-SRS的破裂率为11.1%(95%CI 8.4%-14.5%,I²=28.5%),新发癫痫率为5.5%(95%CI 3.5%-8.5%,I²=0%),放射性坏死为10.4%(95%CI 6.8%-15.6%,I²=41.7%),AVM相关死亡率为6%(95%CI 4%-8.9%,I²=13.7%)。
  • 总剂量≥35 Gy组 vs <35 Gy组的DSA确认闭塞率为60.9% vs 47.8%(p=0.57),放射性坏死为19.9% vs 8.2%(p=0.02)。
  • 分次剂量≥7 Gy组 vs <7 Gy组的闭塞率为53.5% vs 44.5%(p=0.64),放射性坏死为18% vs 6.2%(p=0.01)。
  • 光子组 vs 质子组的血管造影闭塞率为50.7% vs 48%(p=0.86),随访破裂为10.3% vs 9.6%(p=0.9),AVM相关死亡率为5.4% vs 7.4%(p=0.5);光子组中较高Spetzler-Martin级别AVM比例更高(82.2% vs 55.3%,p<0.01),分次剂量更低(7.2 vs 11.1 Gy,p<0.01)。

局限性

  • HF-SRS在AVM中的应用存在显著异质性。
  • 需要进一步研究并统一报告及纳入既往、辅助和挽救治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Obliteration of intracranial arteriovenous malformations (AVMs) with radiosurgery is challenging because high radiation doses prescribed for better effectiveness can increase procedural risks. To minimize adverse effects, fractionation protocols ensure delivery of equivalent or higher total radiation in manageable doses. Hypofractionated stereotactic radiosurgery (HF-SRS), a fractionation strategy using doses exceeding 2 Gy per fraction, requires fewer treatment sessions. The authors conducted a systematic literature review to meta-analyze potential benefits of HF-SRS compared with conventional fractionation regimens. METHODS: PubMed and Embase were searched for literature on "hypofractionated," "radiosurgery," and "arteriovenous malformations." Data including patient and AVM characteristics, procedural details, and outcomes were extracted from eligible studies. Meta-analyses were performed on variables reported by ≥ 3 studies. Subgroup analyses were conducted for photon- and proton-based HF-SRS. RESULTS: The authors included 29 studies comprising 995 patients. For HF-SRS, digital subtraction angiography (DSA) confirmed a 50.1% obliteration rate (95% CI 35.2%-64.9%, I2 = 85.3%) at 41.2 months (95% CI 35.3-48.1 months, I2 = 95%) of follow-up, with an associated 11.1% (95% CI 8.4%-14.5%, I2 = 28.5%) rupture rate, 5.5% (95% CI 3.5%-8.5%, I2 = 0%) new-onset seizure rate, 10.4% (95% CI 6.8%-15.6%, I2 = 41.7%) radionecrosis, and 6% (95% CI 4%-8.9%, I2 = 13.7%) AVM-related mortality. Studies comparing total HF-SRS doses ≥ 35 Gy with < 35 Gy demonstrated trends toward higher rates of DSA-confirmed obliteration (60.9% vs 47.8%, p = 0.57) and radionecrosis (19.9% vs 8.2%, p = 0.02) with higher doses. Similarly, per-fraction doses ≥ 7 Gy showed higher obliteration trends (53.5% vs 44.5%, p = 0.64) and radionecrosis rates (18% vs 6.2%, p = 0.01) compared with < 7-Gy/fraction doses, indicating a dose-response relationship. Photon-based and proton-based HF-SRS resulted in comparable rates of angiographic obliteration (50.7% vs 48%, p = 0.86), follow-up rupture (10.3% vs 9.6%, p = 0.9), and AVM-related mortality (5.4% vs 7.4%, p = 0.5), despite a greater proportion of higher Spetzler-Martin grade AVMs in the photon-based studies (82.2% vs 55.3%, p < 0.01) with lower doses per fraction (7.2 vs 11.1 Gy, p < 0.01). CONCLUSIONS: HF-SRS is a promising radiosurgical strategy for AVMs with no statistically significant differences in effectiveness and adverse effects between photon- or proton-based therapies. There is notable heterogeneity in the application of HF-SRS for AVMs, necessitating further investigations with consistent reporting and incorporation of prior, adjuvant, and salvage treatments for AVMs.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Jaikumar V, Rho K, Nobrega N, et al. Hypofractionated radiosurgery for intracranial arteriovenous malformations: a systematic review and meta-analysis. J Neurosurg. 2025. PMID: 40446353. doi:10.3171/2025.2.JNS242169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。